ClinicalTrials.gg
Active, not recruitingNCT06660173Updated Sep 11, 2026

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 2 interventional study of Maridebart Cafraglutide and Placebo in Type 2 Diabetes Mellitus (T2DM), sponsored by Amgen. Active, not recruiting at 96 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
409
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetes Mellitus, Type 2 by Amgen — 3 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Amgen.

Enrollment
6th of 16
409 · median 221
Started
2024
the only one that year
Phase 2
6 of 16
none open now
Registered
10th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 2 by Amgen, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 2, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 16 studies in Diabetes Mellitus, Type 2 by Amgen are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 2 by Amgen, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Obesity
  • AMG 133
  • T2DM
  • Hemoglobin A1C (HbA1c)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at screening (or ≥ legal age within the country if it is older than 18 years)
  • Type 2 diabetes for ≥6 months according to the World Health Organization classification
  • of 7.0% to 10.5%, inclusive, as assessed by the central laboratory
  • Treatment of diabetes with diet and exercise alone, or with a stable dose of metformin, with or without a sodium-glucose cotransporter-2 inhibitor, for at least 3 months prior to screening
  • of 23 to 50 kilograms per square meter

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Use of any glucose-lowering medication, other than metformin with or without a sodium-glucose cotransporter-2 inhibitor, within 3 months prior to screening
  • Estimated (eGFR) \<30 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology equation.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy
  • History of acute or chronic pancreatitis
  • within 5 years before screening, except for nonmelanoma skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer
  • Myocardial infarction, unstable angina, coronary artery bypass graft surgery or other major cardiovascular surgery, percutaneous coronary intervention, , cerebrovascular accident, or decompensated congestive heart failure within 90 days prior to screening, or currently have Class III or IV heart failure.
  • Use of medications that affect glucose control or body weight or history of bariatric surgery or procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
409 participants (actual)

Study arms

  • Experimental
    Maridebart Cafraglutide

    Participants will be randomized to receive maridebart cafraglutide at varying dose levels, or placebo, for up to 24 weeks. Participants who complete the 24-week Part 1 treatment period and meet specific criteria will have the option to begin an exploratory part 2 where they will be re-randomized to receive maridebart cafraglutide for an additional 24 weeks. Participants who complete the 24-week Part 2 treatment period and meet specific criteria will have the option to begin an exploratory part 3 where they will be re-randomized to receive maridebart cafraglutide for an additional 24 weeks.

    Drug: Maridebart Cafraglutide

  • Placebo comparator
    Placebo

    Participants will be randomized to receive maridebart cafraglutide at varying dose levels, or placebo, for up to 24 weeks. Participants who complete the 24-week Part 1 treatment period and meet specific criteria will have the option to begin an exploratory part 2 where they will be re-randomized to receive maridebart cafraglutide for an additional 24 weeks. Participants who complete the 24-week Part 2 treatment period and meet specific criteria will have the option to begin an exploratory part 3 where they will be re-randomized to receive maridebart cafraglutide for an additional 24 weeks.

    Drug: Placebo

Interventions

  • Solution for subcutaneous injection.

    Also known as: AMG 133

  • DrugPlacebo

    Solution for subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline to Week 24 in Body Weight

    Time frame: Baseline to Week 24

  2. Number of Participants Achieving HbA1c < 7.0% at Week 24

    Time frame: Week 24

  3. Number of Participants Achieving HbA1c ≤ 6.5% at Week 24

    Time frame: Week 24

  4. Number of Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 24

    Time frame: Week 24

  5. Number of Participants Achieving ≥ 10% Reduction in Body Weight From Baseline at Week 24

    Time frame: Week 24

  6. Change From Baseline to Week 24 in Fasting Glucose

    Time frame: Baseline to Week 24

  7. Percent Change From Baseline to Week 24 in Total Cholesterol

    Time frame: Baseline to Week 24

  8. Percent Change From Baseline to Week 24 in Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline to Week 24

  9. Percent Change From Baseline to Week 24 in High-density Lipoprotein Cholesterol (HDL-C)

    Time frame: Baseline to Week 24

  10. Percent Change From Baseline to Week 24 in Non-high Density Lipoprotein Cholesterol (non-HDL-C)

    Time frame: Baseline to Week 24

  11. Percent Change From Baseline to Week 24 in Very-low-density Lipoprotein Cholesterol (VLDL-C)

    Time frame: Baseline to Week 24

  12. Percent Change From Baseline to Week 24 in Triglycerides

    Time frame: Baseline to Week 24

  13. Percent Change From Baseline to Week 24 in Free Fatty Acids (FFA)

    Time frame: Baseline and Week 24

  14. Change From Baseline to Week 24 in Systolic Blood Pressure

    Time frame: Baseline and Week 24

  15. Change From Baseline to Week 24 in Diastolic Blood Pressure

    Time frame: Baseline and Week 24

  16. Change from Baseline to Week 24 in High-sensitivity C-reactive Protein

    Time frame: Baseline and Week 24

  17. Pre-dose Plasma Concentration of Maridebart Cafraglutide at Week 20

    Time frame: Week 20

  18. Maximum Observed Plasma Concentration of Maridebart Cafraglutide at Week 20

    Time frame: Week 20

  19. Number of Participants with Treatment Emergent Adverse Events

    Time frame: Up to 24 Weeks

  20. Number of Participants with Serious Adverse Events

    Time frame: Up to 24 Weeks

  21. Number of Participants with Anti-maridebart Cafraglutide Antibody Formation

    Time frame: Up to Week 24

07

Study locations

96 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Oct 2025, 10 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 28, 2024
StartActual
Nov 7, 2024
Primary completionActual
Oct 6, 2025
CompletionEst.
Nov 10, 2026
Results delay requested
Sep 10, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06660173
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Nov 7, 2024
Primary completion
Oct 6, 2025
Completion
Nov 10, 2026 (estimated)
Last update
Sep 11, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion